Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks.In addition to the Zacks Rank ...

Group 1: Company Overview - Ashtead Group PLC (ASHTY) is part of the Industrial Products group, which consists of 189 companies and ranks 1 in the Zacks Sector Rank [2] - The Zacks Rank is a stock-picking model that focuses on earnings estimates and revisions, with ASHTY currently holding a Zacks Rank of 2 (Buy) [3] Group 2: Performance Metrics - Over the past 90 days, the Zacks Consensus Estimate for ASHTY's full-year earnings has increased by 12.5%, indicating improved analyst sentiment [4] - ASHTY has returned 20.7% year-to-date, outperforming the average return of 6.6% for the Industrial Products sector [4] - In the Industrial Services industry, which includes 18 stocks, ASHTY is performing better than the average gain of 6% so far this year [6] Group 3: Comparative Analysis - Life360 (LIF) is another stock in the Industrial Products sector that has significantly outperformed, with a year-to-date return of 142.3% and a consensus EPS estimate increase of 29.2% over the past three months [5] - The Security and Safety Services industry, which includes Life360, has seen a year-to-date increase of 26.7% [7]

Group 1 - Everus Construction Group, Inc. (ECG) is currently ranked 13 in the Zacks Sector Rank among 88 companies in the Construction group [2] - ECG has a Zacks Rank of 1 (Strong Buy), indicating a positive earnings outlook based on earnings estimates and revisions [3] - The Zacks Consensus Estimate for ECG's full-year earnings has increased by 15.4% in the past quarter, reflecting stronger analyst sentiment [4] Group 2 - ECG has returned approximately 19.9% year-to-date, outperforming the average return of 5.5% for Construction companies [4] - ECG belongs to the Building Products - Miscellaneous industry, which is ranked 146 in the Zacks Industry Rank, with an average gain of 0.6% this year [6] - In comparison, MasTec (MTZ), another Construction stock, has returned 42% year-to-date and belongs to the Building Products - Heavy Construction industry, currently ranked 4 with a year-to-date increase of 34.1% [5][7]

In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Summit Therapeutics Inc. stands amongst them. Summit Therapeutics Inc. (NASDAQ:SMMT), a biopharmaceutical company focused on non-small cell lung cancer (NSCLC), has made significant strides with its lead investigational drug, ivonescimab. The HARMONi Phase III trial for EGFR-mutated NSCLC patients demonstrated a statistically significant improvement in progression-free survival when ivonescimab was combined ...

Getting out of debt can be challenging and complex. Short of making minimum payments to chip away at your credit card bills or earning extra money through a side gig, just how do you avoid the dreaded debt collector? Be Aware: Key Signs Your Credit Card Is Quietly Wrecking Your Finances Up Next: 7 Ways To Tell If You're Rich or Middle Class -- It's More Than Your Paycheck Dealing with debt is different for everyone, but the second step in Dave Ramsey’s debt management plan is one approach to getting out f ...

In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Glaukos Corporation stands seventh among them. Glaukos Corporation (NYSE:GKOS), a leader in ophthalmic pharmaceutical and surgical therapies, continues to expand its presence in glaucoma, corneal disorders, and retinal diseases through innovative “dropless” treatment platforms. Its FDA-approved iDose sustained-release implant delivers continuous glaucoma therapy directly inside the eye, improving patient ad ...

In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Qiagen N.V. is one of them. Qiagen N.V. (NYSE:QGEN), a global leader in molecular diagnostics and sample preparation, continues to expand its precision medicine footprint through innovative testing solutions for infectious diseases, cancer genomic profiling, and cell and gene therapy quality control. In Q2 2025, the business reported 7% net sales growth year-over-year, driven by strong adoption of key prod ...

Core Insights - Telix Pharmaceuticals Limited is recognized as one of the most oversold healthcare stocks in 2025, focusing on precision oncology and targeted radiotherapies with active clinical programs in prostate cancer and rare oncologic conditions [1] Financial Performance - In the 2025 half-year update, Telix reported a 30% revenue increase in its Precision Medicine segment, driven by strong demand for its PET imaging agent, Illuccix, and the launch of new products like Gozellix, Zircaix, and Pixclara in international markets [2] - The company has expanded its manufacturing capabilities through Telix Manufacturing Solutions to support clinical and commercial operations globally [2] Research and Development - Telix increased its R&D spending by 47% year-over-year to $81.6 million, continuing to invest in its therapeutics pipeline despite being oversold [3] - Key milestones include the completion of target enrollment for the Phase 3 TLX591 trial in advanced metastatic castration-resistant prostate cancer (mCRPC), initiation of a Phase 1 trial for TLX592, and the start of the pivotal IPAX BrIGHT trial for TLX101 in metastatic brain cancer [3][4] - The company also gained IND approval for a Phase 1 study of TLX090 to manage bone pain in osteoblastic metastatic disease [3] Strategic Positioning - Diagnostic growth is further supported by the dosing of the first patient in the pivotal Phase 3 BiPASS trial, aimed at expanding indications for Illuccix and Gozellix in prostate cancer imaging [4] - Telix's dual strategy of commercial expansion and clinical innovation positions it as a leader in radiopharmaceuticals and precision oncology globally [4]

Cracker Barrel Old Country Store, Inc. CBRL reported downbeat fourth-quarter earnings and provided FY2026 sales guidance below analyst expectations on Wednesday.Cracker Barrel reported fourth-quarter revenue of $868.09 million, beating analyst estimates of $855.30 million, according to Benzinga Pro. The company reported fourth-quarter adjusted earnings of 74 cents per share, missing analyst estimates of 80 cents per share."We thank our guests for sharing their voices and their passion for Cracker Barrel in ...

In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Prestige Consumer Healthcare Inc. stands amongst them. Prestige Consumer Healthcare Inc. (NYSE:PBH), a global developer of OTC health and personal care products, is taking strategic steps to secure growth in its eye care business amid operational challenges in 2025. In August 2025, Prestige Consumer Healthcare Inc. (NYSE:PBH) acquired Pillar5 Pharma, a key supplier of multi-dose sterile ophthalmic products ...